Elevance Health ELV has been analyzed by 12 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 8 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 4 | 6 | 0 | 0 | 0 |
| 3M Ago | 0 | 1 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $595.0, a high estimate of $649.00, and a low estimate of $557.00. Surpassing the previous average price target of $577.25, the current average has increased by 3.07%.
Understanding Analyst Ratings: A Comprehensive Breakdown
The analysis of recent analyst actions sheds light on the perception of Elevance Health by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Michael Ha | Baird | Announces | Outperform | $649.00 | - |
| Ann Hynes | Mizuho | Raises | Buy | $585.00 | $575.00 |
| Ben Hendrix | RBC Capital | Raises | Outperform | $575.00 | $574.00 |
| A.J. Rice | UBS | Raises | Buy | $605.00 | $585.00 |
| Stephen Baxter | Wells Fargo | Raises | Overweight | $600.00 | $557.00 |
| David Macdonald | Truist Securities | Raises | Buy | $600.00 | $580.00 |
| David Windley | Jefferies | Raises | Buy | $604.00 | $602.00 |
| Andrew Mok | Barclays | Raises | Overweight | $621.00 | $584.00 |
| Sarah James | Cantor Fitzgerald | Maintains | Overweight | $580.00 | - |
| Stephen Baxter | Wells Fargo | Lowers | Overweight | $557.00 | $561.00 |
| Sarah James | Cantor Fitzgerald | Maintains | Overweight | $580.00 | - |
| Andrew Mok | Barclays | Announces | Overweight | $584.00 | - |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Elevance Health. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Elevance Health compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Elevance Health's stock. This comparison reveals trends in analysts' expectations over time.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Elevance Health's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Elevance Health analyst ratings.
All You Need to Know About Elevance Health
Elevance Health remains one of the leading health insurers in the U.S., providing medical benefits to 47 million medical members as of December 2023. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states through government-sponsored programs such as Medicaid and Medicare Advantage plans, too.
Breaking Down Elevance Health's Financial Performance
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Elevance Health displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 0.96%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 5.28%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Elevance Health's ROE excels beyond industry benchmarks, reaching 5.62%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Elevance Health's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.03% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.65, caution is advised due to increased financial risk.
The Significance of Analyst Ratings Explained
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
